In yesterday’s Wall Street session, LivaNova PLC (NASDAQ:LIVN) shares traded at $55.94, up 0.13% from the previous session.
LIVN stock price is now 7.26% away from the 50-day moving average and 8.49% away from the 200-day moving average. The market capitalization of the company currently stands at $3.02B.
On February 20, 2024, Mizuho Upgraded its previous ‘Neutral’ rating to ‘Buy’ on the stock increasing its target price from $60 to quote $70, while ‘HSBC Securities’ rates the stock as ‘Hold’
In other news, McDonald Damien, CEO sold 2,220 shares of the company’s stock on Mar 30 ’23. The stock was sold for $94,461 at an average price of $42.55. Upon completion of the transaction, the CEO now directly owns 111,847 shares in the company, valued at $6.26 million. A total of 0.47% of the company’s stock is owned by insiders.
During the past 12 months, LivaNova PLC has had a low of $41.87 and a high of $59.86. As of last week, the company has a debt-to-equity ratio of 0.50, a current ratio of 2.95, and a quick ratio of 2.51. The fifty day moving average price for LIVN is $52.15 and a two-hundred day moving average price translates $51.56 for the stock.
The latest earnings results from LivaNova PLC (NASDAQ: LIVN) was released for Dec, 2023. According to the Medical Devices Company, earnings per share came in at $0.87, beating analysts’ expectations of $0.77 by 0.1. This compares to $0.03 EPS in the same period last year. The net profit margin was 1.52% and return on equity was 1.41% for LIVN. The company reported revenue of $310.13 million for the quarter, compared to $274.87 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 12.83 percent. For the current quarter, analysts expect LIVN to generate $278.19M in revenue.
LivaNova PLC(LIVN) Company Profile
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products. The Neuromodulation segment designs, develops, markets, and sells VNS Therapy System, an implantable pulse generator and connective lead that stimulates the vagus nerve; difficult-to-treat depression and drug-resistant epilepsy devices. The Advanced Circulatory Support segment develops, produces, and sells temporary life support products. It serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. The company sells its products through direct sales representatives and independent distributors. LivaNova PLC was incorporated in 2015 and is headquartered in London, the United Kingdom.
